Anavar 25 mg 100 Tablets Hutech Labs USA
$179.00
Product Short Description
Anavar 25 mg 100 Tablets Hutech Labs USA delivers oxandrolone (C19H30O3) at balanced 25 mg potency bridging prescription 10 mg and institutional 50 mg formats within a 100-tablet sealed bottle matching DEA Schedule III standards. Domestic production serves informed buyers through verified U.S. channels with discreet fulfillment.
Product Overview
Hutech Labs USA’s Anavar 25 mg presents oxandrolone, the C2-oxa DHT derivative anabolic steroid, in scored white tablets exhibiting pharmaceutical-grade specifications (molecular weight 306.44) for institutional performance catalogs. The 100-tablet tamper-evident configuration supports CIII-compliant inventory management across encrypted specialist platforms requiring precise potency declaration and batch traceability.
U.S. domestic manufacturing eliminates customs exposure while maintaining USP-equivalent morphology distinguishing legitimate Schedule III supply from underground conversions prevalent in non-verified markets. This intermediate dosage serves advanced resellers managing structured DEA-regulated workflows rather than pharmaceutical or recreational crossover.
Anavar 25 mg targets verified CIII ecosystems emphasizing commercial positioning without protocols, cycles, or therapeutic claims.
Brand & Manufacturer Information
Hutech Labs USA produces Schedule III anabolics through domestic facilities serving institutional performance distribution requiring controlled substance compliance. The 25 mg/100-tab specification maintains catalog continuity alongside Hutech high-potency orals while authenticating legitimate institutional product versus powder-pressed alternatives.
Domestic warehousing supports DEA Form 222 record-keeping across encrypted platforms confirming oxandrolone identity/potency.
Active Compound Information
Contains oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) featuring high anabolic:androgenic dissociation (~10:1) characteristic of 17α-alkylated C2-oxa steroids enabling oral bioavailability without aromatization. DEA Schedule III (21 CFR 1308.13) reflects hepatotoxicity profile at performance dosing beyond prescription 2.5-10 mg Oxandrin.
25 mg strength represents 2.5-10× pharmaceutical while maintaining C17α-methylation preventing first-pass metabolism. WADA S1a prohibited globally.
Product Specifications
| Specification | Details |
|---|---|
| Product Name | Anavar 25 mg 100 Tablets Hutech Labs USA |
| Active Compound | Oxandrolone (C19H30O3) |
| Strength | 25 mg per scored tablet |
| Quantity | 100 tablets per bottle |
| Form | Oral scored tablets |
| Category | DEA Schedule III controlled substance |
| Packaging | Tamper-evident HDPE bottle |
| Label Elements | 25 mg declaration, batch/expiry, CIII warnings |
Quality Control & Testing Standards
25 mg oxandrolone requires USP potency assay (90-110% HPLC), dissolution profiling, and uniformity verification bridging pharmaceutical and performance standards. Hutech batch documentation confirms C19H30O3 identity and Schedule III-compliant excipients.
100-tablet institutional bottling prevents diversion matching DEA pharmacy protocols; domestic stability maintains product integrity.
Intended Use & Market Positioning
Serves CIII-licensed institutional researchers managing intermediate-dosage DEA Schedule III inventories. 25 mg/100-tab excludes crossover within premium domestic catalogs. No protocols represented.
Legal & Regulatory Disclaimer
Oxandrolone constitutes DEA Schedule III under 21 USC §812; non-medical handling violates Controlled Substances Act. Buyer assumes Form 222 compliance; zero medical claims provided.
You must be logged in to post a review.
Reviews
There are no reviews yet.